Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models

Cancer Gene Therapy

Volumn 17, Issue 6, 2010, Pages 387-397

  Rousseau, J ^a,b   Escriou, V ^c   Perrot, P ^a,b,d   Picarda, G ^a,b   Charrier, C ^a,b   Scherman, D ^c   Heymann, D ^a,b   Redini F ^a,b   Trichet, V ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d HÔTEL DIEU   (France)

Author keywords

Bioluminescence imaging; Efficient delivery; Osteosarcoma; RNA interference

Indexed keywords

FIREFLY LUCIFERASE; IFOSFAMIDE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BONE DEVELOPMENT; CELL DEATH; CONTROLLED STUDY; GENE EXPRESSION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR VOLUME;

MUS;

EID: 77952547972     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.89     Document Type: Article

References (41)

1. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007, 2, 6.
2. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metas-tases. J Clin Oncol 1994; 12: 1849-1858.
3. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001; 12: 1145-1150.
4. Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F. Recent advances in the management of osteosar-coma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther 2007; 7: 169-181.
5. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007; 6: 2609-2617.
6. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001; 61: 2572-2578.
7. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98: 11581-11586.
8. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003; 63: 7883-7890.
9. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98: 3534-3540.
10. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61: 4432-4436.
11. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440: 692-696.
12. Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res 2007; 67: 202-208.
13. Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007; 67: 7308-7318.
14. Lamoureux F, Picarda G, Rousseau J, Gourden C, Battaglia S, Charrier C et al. Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther 2008; 7: 3389-3398.
15. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007; 9(Suppl 1): S7.
16. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006; 13: 464-477.
17. Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Hobel S et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006; 17: 751-766.
18. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005; 12: 634-643.
19. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984-8992.
20. Wang D, Zhong ZY, Li MX, Xiang DB, Li ZP. Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo. Cancer Sci 2007; 98: 1993-2001.
21. Wang R, Dong K, Lin F, Wang X, Gao P, Wei SH et al. Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med 2007; 13: 567-575.
22. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006; 11: 67-73.
23. De Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008; 19: 125-132.
24. Takeshita F, Hokaiwado N, Honma K, Banas A, Ochiya T. Local and systemic delivery of siRNAs for oligonucleotide therapy. Methods Mol Biol 2009; 487: 83-92.
25. Cherrier B, Gouin F, Heymann MF, Thiery JP, Redini F, Heymann D et al. A new experimental rat model of osteosarcoma established by intrafemoral tumor cell inoculation, useful for biology and therapy investigations. Tumour Biol 2005; 26: 121-130.
26. Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 2006; 54: 1867-1877.
27. Rhinn H, Largeau C, Bigey P, Kuen RL, Richard M, Scherman D et al. Escriou how to make siRNA lipoplexes efficient? Add a DNA cargo. Biochim Biophys Acta 2009; 1790: 219-230.
28. Jasmin C, Allouche M, Jude JG, Klein B, Thiery JP, Perdereau B et al. An experimental model of osteosarcomas in rats. Sem Hop 1982; 58: 1684-1689.
29. Uesugi M, Koshino T, Mitsugi N, Hiruma T. Predictive value of serum immunosuppressive acidic protein for lung metastasis after amputation of murine osteosarcoma of the lower limb. Cancer Lett 2000; 155: 169-172.
30. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813.
31. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-188.
32. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
33. Chipoy C, Berreur M, Couillaud S, Pradal G, Vallette F, Colombeix C et al. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res 2004; 19: 1850-1861.
34. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005; 37: 74-86.
35. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14-18.
36. Haussecker D. The business of RNAi therapeutics. Hum Gene Ther 2008; 19: 451-462.
37. Nguyen T, Menocal EM, Harborth J, Fruehauf JH. RNAi therapeutics: an update on delivery. Curr Opin Mol Ther 2008; 10: 158-167.
38. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009; 19: 89-102.
39. Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008; 19: 991-999.
40. Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem 2007; 102: 1333-1342.
41. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989; 8: 98-101.